First patient in Serbia with biochemically and genetically diagnosed pyridoxine-dependent epilepsy

Miloš M Ješić; Maja D Ješić; Svetlana Buljugić; Aleksandra Živanović

doi:10.2298/VSP150311244J

Miloš M Ješić University Children’s Hospital, Belgrade, Serbia; University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Maja D Ješić University Children’s Hospital, Belgrade, Serbia; University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Svetlana Buljugić University Children’s Hospital, Belgrade, Serbia
Aleksandra Živanović University Children’s Hospital, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP150311244J

Keywords: epilepsy, infant, newborn, vitamin B6, genetic diseases, inborn, diagnosis, differential, drug therapy, serbia,

Abstract

Introduction. Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive inborn error of metabolism present with early-onset seizures resistant to common anticonvulsants. PDE has been shown to be caused by a defect of a α-aminoadipic semialdehyde dehydrogenase (also known as ALDH7A1 or antiquitin) in the cerebral lysine degradation pathway. Its deficiency results in accumulation of α-aminoadipic semialdehyde (α-AASA), piperideine -6-carboxylate and pipecolic acid, which serve as diagnostic markers in urine, plasma and cerebrospinal fluid of the disease. α-Aminoadipic semialdehyde dehydrogenase is encoded by the ALDH7A1 or antiquitin gene and definite confirmation of diagnosis of PDE is made by genetic analysis. Case report. We present a first patient in Serbia who was diagnosed clinically, biochemically and genetically. We suspected PDE due to drug-resistant seizures in the seventh day of life when we attempted with pyridoxine. Since that time the patient has taken pyridoxine and the seizures have not recured. Our patient had markedly elevated α-AASA in urine while on treatment with individual dosages of pyridoxine. Molecular-genetical analysis identified mutations of the ALDH7A1 (antiquitin) gene. Conclusion. α-AASA is reliable marker to select PDF patient for molecular analysis of the ALDH7A1(antiquitin) gene. Diagnosis is confirmed by molecular-genetical analysis and pyridoxine withdrawal is no longer needed to establish the diagnosis of „definite“ PDE.

References

Genetic Testing Registry. Pyridoxine-dependent epilepsy.

Available from:

http://ghr.nlm.gov/condition/pyridoxine-dependent-epilepsy

Stockler S, Plecko B, Gospe SM, Coulter-Mackie M, Connolly M, van Karnebeek C, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: Clinical and molecular characteristics and recom-mendations for diagnosis, treatment and follow-up. Mol Genet Metab 2011; 104(1−2): 48−60.

Plecko B, Paul K, Paschke E, Stoeckler-Ipsiroglu S, Struys E, Jakobs C, et al. Biochemical and molecular characterization of 18 pa-tients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat 2007; 28(1): 19−26.

Gospe SM Jr, Hecht ST. Longitudinal MRI findings in pyridox-ine-dependent seizures. Neurology 1998; 51(1): 74−8.

Gospe SM. Pyridoxine-dependent seizures: Findings from recent studies pose new questions. Pediatr Neurol 2002; 26(3): 181−5.

Baxter P. Pyridoxine-dependent and pyridoxine-responsive seizures. Dev Med Child Neurol 2001; 43(6): 416−20.

Basura GJ, Hagland SP, Wiltse AM, Gospe SM. Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: Review of 63 North American cases submitted to a patient registry. Eur J Pediatr 2009; 168(6): 697−704.

Gospe SM. Pyridoxine-Dependent Epilepsy and Related Condi-tions. In: Pearl PL, editor. Inherited Metabolic Epilepsies. New York: Demos Medical Publishing; 2013. p. 145−76.

Peduto A, Baumgartner MR, Verhoeven NM, Rabier D, Spada M, Nassogne M, et al. Hyperpipecolic acidaemia: A diagnostic tool for peroxisomal disorders. Mol Genet Metab 2004; 82(3): 224−30.

Mills PB, Footitt EJ, Mills KA, Tuschl K, Aylett S, Varadkar S, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 2010; 133(Pt 7): 2148−59.

Millet A, Salomons GS, Cneude F, Corne C, Debillon T, Jakobs C, et al. Novel mutations in pyridoxine-dependent epilepsy. Eur J Paediatr Neurol 2011; 15(1): 74−7.

Mills PB, Struys E, Jakobs C, Plecko B, Baxter P, Baumgartner M, Clayton PT. Mutations in antiquitin in individuals with pyridox-ine-dependent seizures. Nat Med 2006; 12(3): 307−9.

Bok LA, Halbertsma FJ, Houterman S, Wevers RA, Vreeswijk C, Jakobs C, et al. Long-term outcome in pyridoxine-dependent epilepsy. Dev Med Child Neurol 2012; 54(9): 849−54.

Mills PB, Footitt EJ, Ceyhan S, Waters PJ, Jakobs C, Clayton PT, et al. Urinary AASA excretion is elevated in patients with molyb-denum cofactor deficiency and isolated sulphite oxidase defi-ciency. J Inherit Metab Dis 2012; 35(6): 1031−6.

Veldman A, Santamaria-Araujo JA, Sollazzo S, Pitt J, Gianello R, Yaplito-Lee J, et al. Successful treatment of molybdenum cofac-tor deficiency type A with cPMP. Pediatrics 2010; 125(5): e1249−54.